Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has earned a consensus rating of "Hold" from the ten analysts that are covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $10.78.

Several research analysts recently weighed in on ZNTL shares. Wedbush raised Zentalis Pharmaceuticals from an "underperform" rating to a "neutral" rating and set a $4.00 target price for the company in a research note on Monday, August 12th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday, August 12th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Anfield Capital Management LLC purchased a new stake in Zentalis Pharmaceuticals in the 2nd quarter worth about $40,000. 49 Wealth Management LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the 1st quarter worth about $172,000. Kennedy Capital Management LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the 1st quarter worth about $189,000. Carson Advisory Inc. purchased a new stake in shares of Zentalis Pharmaceuticals during the 1st quarter worth about $201,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company's stock worth $50,000 after purchasing an additional 5,333 shares in the last quarter.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL traded up $0.41 during trading hours on Monday, reaching $3.73. 2,852,488 shares of the company's stock traded hands, compared to its average volume of 1,325,433. The firm has a market capitalization of $265.23 million, a price-to-earnings ratio of -1.37 and a beta of 1.74. Zentalis Pharmaceuticals has a twelve month low of $2.66 and a twelve month high of $18.24. The business's fifty day simple moving average is $3.30 and its two-hundred day simple moving average is $5.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings results on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.40). During the same quarter in the prior year, the business earned ($1.85) earnings per share. On average, equities research analysts expect that Zentalis Pharmaceuticals will post -3.02 EPS for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.